Auvelity Tablet, Multilayer, Extended Release
Product Images NDC 81968-030
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Auvelity (NDC 81968-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Axsome Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Structural Formula (Bupropion Hydrochloride)
Figure 1 (Auvelity 03)
Figure 2 (Auvelity 04)
This appears to be the output of statistical analysis, including the mean effect and 90% confidence interval for several drugs and their corresponding inhibitors or inducers. Specifically, the analysis mentions the effect of Paroxetine and Clopidogrel, and the inhibitors or inducers of CYP2D6 and CYP286. The text also includes some numerical values for various drugs, such as Carbamazepine, and their corresponding drug concentrations over time. Additionally, there is a section on changes relative to a reference.*
Figure 3 (Auvelity 05)
30-count Bottle Label (Auvelity 06)
This is a medication called Auvelity, an extended-release tablet which contains 45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride. It is used as per the prescribing information and should be stored at temperatures between 20°C to 25°C (68°F to 77°F). This medication is manufactured by Axsome Therapeutics and is available in a bottle containing 30 tablets. It is to be swallowed whole without crushing, dividing, or chewing, and it is not to be used if the seal is broken. The accompanying medication guide should be carefully read before use.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.